Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifirafenib in Chinese patients with advanced solid tumors
NCT03641586Phase 1Completed
- Sponsor
- BeiGene
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lifirafenib in solid tumor and melanoma (3 arms), sponsored by BeiGene. Primary endpoints: Number of participants with treatment-related adverse events at 1 year, Objective Response Rate at 1 year and 6 more. Started Oct 2015; status: completed.
02
Drugs
lifirafenib
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT03641586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641586.